Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.
Τίτλος | Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Trachana, M., Pratsidou-Gertsi P., Badouraki M., Haidich A. Bettina, & Pardalos G. |
Journal | Clin Rheumatol |
Volume | 32 |
Issue | 8 |
Pagination | 1191-7 |
Date Published | 2013 Aug |
ISSN | 1434-9949 |
Λέξεις κλειδιά | Adolescent, Antirheumatic Agents, Arthritis, Juvenile, Child, Etanercept, Female, Humans, Immunoglobulin G, Joints, Male, Receptors, Tumor Necrosis Factor, Registries, Remission Induction, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome, Uveitis |
Abstract | The objective of this retrospective study was to record the achievement of clinical remission (CR) in juvenile idiopathic arthritis patients under a 2-10 years' administration of Etanercept (ETN) and to detect any variables associated with CR. Patients previously resistant to conventional regimens were enrolled. The annual impact of ETN was assessed by: (a) the American College of Rheumatology pediatric criteria (ACRpedi), (b) the pre- and posttreatment disease activity score (juvenile arthritis disease activity score [JADAS71]), and (c) Wallace's criteria for CR. A total of 41 patients (F: 31) were registered. The median age and disease duration at baseline were 10.6 and 4.17 years, respectively, and their disease course was mainly polyarthritis (32/41). In respect to baseline, there was an impressive JADAS71 reduction posttreatment, most prominent after the first year. From year 1 to 5, more than 50 % of the patients achieved and retained CR and 66 % reached an ACRpedi 70, whereas after the 5th year, no patient was withdrawn due to an ACRpedi <30. JADAS71 at baseline was not associated with the subsequent CR achievement. However, JADAS71 1-year posttreatment had a significant association with the CR of the second posttreatment year, (p = 0.028, OR 0.79; 95 % CI 0.63-0.98) and a similar trend was observed for the following years. These findings emphasize the sustained impact of ETN in the achievement of CR. A low JADAS71 score 1-year posttreatment, may be associated with the maintenance of CR over the next treatment year. |
DOI | 10.1007/s10067-013-2261-z |
Alternate Journal | Clin. Rheumatol. |
PubMed ID | 23604548 |